ES2113892T3 - Inmunoreactivos radiactivos dirigidos. - Google Patents

Inmunoreactivos radiactivos dirigidos.

Info

Publication number
ES2113892T3
ES2113892T3 ES91920573T ES91920573T ES2113892T3 ES 2113892 T3 ES2113892 T3 ES 2113892T3 ES 91920573 T ES91920573 T ES 91920573T ES 91920573 T ES91920573 T ES 91920573T ES 2113892 T3 ES2113892 T3 ES 2113892T3
Authority
ES
Spain
Prior art keywords
proteins
alcoxy
reactive group
immunoreactive
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920573T
Other languages
English (en)
Inventor
John L Toner
David A Hilborn
Bruce J Murray
Timothy Z Hossain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Application granted granted Critical
Publication of ES2113892T3 publication Critical patent/ES2113892T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN INMUNOREACTIVO CON FOCO DE EMISION RADIOACTIVO COMPRENDE UN ION METALICO RADIONUCLEOSIDO, UN AGENTE DE COMPLEXION Y UN GRUPO INMUNOREACTIVO LIGADO POR COVALENCIA AL MENCIONADO AGENTE DE COMPLEXION, TENIENDO EL AGENTE DE COMPLEXION UNA ESTRUCTURA (A-I), EN LA QUE R REPRESENTA HIDROGENO, ALQUILO, ALCOXI, ALQUILTIO, ALQUILAMINO, ALQUILFORMAMIDO, ARILO, ARILOXI, HETEROCICLILO O UN GRUPO REACTIVO DE PROTEINAS; R1 REPRESENTA HIDROGENO, ALQUILO, ALCOXI, ALQUILTIO, ALQUILAMINO, ALQUILFORMAMIDO, ARILO, ARILOXI, HETEROCICLILO O UN GRUPO REACTIVO DE PROTEINAS; R2 REPRESENTA HIDROXI, CARBOXI, HIDROXIALQUILO, ACIDO CARBONILIMINOACETICO, ACIDO METILENOIMINODIACETICO, ACIDO METILENOETIOETILENOIMINODIACETICO, ACIDO HIDRACINILILIDENODIACETICO O UNA SAL DE DICHOS ACIDOS, O DOS GRUPOS R2, TOMADOS JUNTOS, REPRESENTAN LOS ATOMOS NECESARIOS PARA COMPLETAR UNA ESTRUCTURA DE ANILLO MACROCICLICO QUE CONTIENE AL MENOS UNA ZONA DE COORDINACION HETEROATOMICA Y AL MENOS UNO, PREFERIBLEMENTE DOS GRUPOS ALQUILENO QUEFORMEN PARTE DE LA ESTRUCTURA DE ANILLO; R3 REPRESENTA HIDROGENO, ALQUIL, ALCOXI, ALQUILTIO, ALQUILAMINO, ALQUILFORMAMIDO, ARILO, ARILOXI, HETEROCICLILO O UN GRUPO REACTIVO DE PROTEINAS; R4 REPRESENTA HIDROGENO O UN GRUPO REACTIVO DE PROTEINAS; N ES DE 0 A 4, O ES DE 0 A 1, M ES 0 O 1; SIEMPRE QUE AL MENOS N O M SEA 0 Y AL MENOS 1 DE ENTRE R, R1, R3 Y R4 SEA UN GRUPO REACTIVO DE PROTEINAS. EN UNA COMPOSICION DE TAL ASPECTO, ESTA INVENCION PROPORCIONA NUEVAS TERPIRIDINAS Y FENANTROLINAS. LAS TERPIRIDINAS PREFERIDAS TIENEN LA ESTRUCTURA (A-I) DE ARRIBA, DONDE N=1, M=0 Y R ES UN FENILO SUSTITUIDO QUE CONTIENE UN SUBSTITUYENTE ALQUILO O ALCOXI Y UN GRUPO REACTIVO DE PROTEINAS. LAS FENANTROLINAS PREFERIDAS TIENEN LA ESTRUCTURA (A-I) DE ARRIBA, DONDE N=0, M=1 Y AL MENOS UN R4 ES UN GRUPO REACTIVO DE PROTEINAS. LOS INMUNOREACTIVOS CON FOCO DE EMISION RADIOACTIVO SON PARTICULARMENTE UTILES EN COMPOSICIONES Y METODOS DE IMAGENES TERAPEUTICAS Y DE DIAGNOSIS.
ES91920573T 1990-11-08 1991-11-07 Inmunoreactivos radiactivos dirigidos. Expired - Lifetime ES2113892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61086190A 1990-11-08 1990-11-08
US07/784,333 US5367080A (en) 1990-11-08 1991-10-29 Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
PCT/US1991/008253 WO1992008494A2 (en) 1990-11-08 1991-11-07 Targeting radioactive immunoreagents

Publications (1)

Publication Number Publication Date
ES2113892T3 true ES2113892T3 (es) 1998-05-16

Family

ID=27086372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920573T Expired - Lifetime ES2113892T3 (es) 1990-11-08 1991-11-07 Inmunoreactivos radiactivos dirigidos.

Country Status (21)

Country Link
US (4) US5367080A (es)
EP (1) EP0624097B1 (es)
JP (1) JP3292301B2 (es)
KR (1) KR930701974A (es)
AT (1) ATE164082T1 (es)
AU (2) AU667030B2 (es)
BR (1) BR9107074A (es)
CA (1) CA2095123A1 (es)
DE (1) DE69129127T2 (es)
DK (1) DK0624097T3 (es)
ES (1) ES2113892T3 (es)
FI (1) FI932083A7 (es)
GR (1) GR3026713T3 (es)
HU (1) HUT67298A (es)
IE (1) IE913907A1 (es)
MX (1) MX9101999A (es)
NO (1) NO931631L (es)
NZ (1) NZ240521A (es)
PT (1) PT99460B (es)
TW (1) TW201271B (es)
WO (1) WO1992008494A2 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
AU672951B2 (en) * 1992-05-07 1996-10-24 Ge Healthcare As Complexing agents and targeting immunoreagents
WO1994009056A1 (en) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Chelating polymers
KR950703955A (ko) * 1992-12-28 1995-11-17 우에하라 아키라 테르피리딘 유도체의 약학적 용도
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
JPH08512019A (ja) * 1993-03-10 1996-12-17 ザ・ウエルカム・ファウンデーション・リミテッド 免疫反応剤およびキレート化された放射性核種からなるｌ−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング
US5744119A (en) * 1993-05-11 1998-04-28 Sterling Winthrop Preparation of a radioconjugate formulation
US5559214A (en) 1993-05-28 1996-09-24 Sterling Winthrop Inc. Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods
AU7244894A (en) * 1993-06-07 1995-01-03 Wellcome Foundation Limited, The Immunoreactive reagents employing monoamine oxidase
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
US5562626A (en) * 1995-09-11 1996-10-08 Sanpietro; Joseph A. Safety syringe
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
WO1998009650A1 (en) 1996-09-06 1998-03-12 Mitsubishi Chemical Corporation Vaccinal preparations
WO1999021587A1 (en) * 1997-10-15 1999-05-06 Nycomed Imaging As Complexing agents and targeting immunoreagents
AU2530199A (en) * 1998-02-06 1999-08-23 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
AU3375599A (en) * 1998-03-31 1999-10-18 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof
US6314314B1 (en) 1999-01-14 2001-11-06 Seth J. Karp Method for locating an internal bleeding site in a human body
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp BINDING CENTERS FOR FIBRIN
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US6727167B2 (en) * 2000-10-13 2004-04-27 Emcore Corporation Method of making an aligned electrode on a semiconductor structure
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2005084179A2 (en) 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
AU2004296184B2 (en) * 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
US20060024229A1 (en) * 2004-07-29 2006-02-02 Seth Karp Method and product for locating an internal bleeding site
US20100034748A1 (en) * 2008-08-07 2010-02-11 Guizhi Li Molecular imaging probes based on loaded reactive nano-scale latex
WO2007022307A2 (en) * 2005-08-16 2007-02-22 University Of North Carolina At Wilmington Ligands for metal ions and methods for making and using the same
US20090098057A1 (en) * 2007-10-16 2009-04-16 Shiying Zheng Silica-cored carrier particle
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
US20080167544A1 (en) * 2006-12-01 2008-07-10 Cold Spring Diagnostics, Inc. Compositions And Methods For Locating An Internal Bleeding Site
CN101558081B (zh) 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
US8906354B2 (en) 2007-02-28 2014-12-09 Bruker Biospin Corporation Loaded latex optical molecular imaging probes containing lipophilic large stokes shift dyes
EP2005970A1 (de) 2007-06-22 2008-12-24 Berlin Science Partners GmbH i.V. Bildgebende Diagnostik durch Kombination von Kontrastmitteln
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
EP2477986B1 (en) * 2009-09-14 2014-11-12 B.R.A.H.M.S GmbH Phenanthroline derivatives and their use as ligands
FR2969999B1 (fr) * 2011-01-03 2013-02-08 Commissariat Energie Atomique Conjugue, son procede de preparation et ses utilisations
US9187690B2 (en) * 2011-03-11 2015-11-17 B.R.A.H.M.S. Gmbh Rare earth metal complex having phenanthroline compound as ligand
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
WO2017137477A1 (en) 2016-02-09 2017-08-17 Bracco Suisse Sa A recombinant chimeric protein for selectins targeting
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3535278A4 (en) 2016-11-01 2020-06-24 Ohio State Innovation Foundation METHOD FOR IODING BIOMOLECULES
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US20200291391A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
EP3972646A4 (en) 2019-05-20 2023-06-14 Ohio State Innovation Foundation APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USE THEREOF
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
JP7801207B2 (ja) 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
IL303925A (en) 2021-01-07 2023-08-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4122499A1 (en) 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof
AU2022397307A1 (en) 2021-11-26 2024-06-06 Full-Life Technologies Uk Limited Cleavable radioligands for targeting cell surface receptors and uses thereof
TW202340226A (zh) 2021-12-17 2023-10-16 德商３Ｂ製藥有限公司 碳酸酐酶ix配位體
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
PE20251640A1 (es) 2022-09-07 2025-06-24 3B Pharmaceuticals Gmbh Ligandos de antigeno de membrana especifica de la prostata (psma) y uso de los mismos
EP4455159A1 (en) 2023-04-25 2024-10-30 3B Pharmaceuticals GmbH Gastric inhibitory peptide receptor ligands with bio-distribution modifier
CN121773094A (zh) 2023-09-12 2026-03-31 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
CN120202191A (zh) 2023-09-12 2025-06-24 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4637988A (en) * 1981-07-01 1987-01-20 Eastman Kodak Company Fluorescent labels for immunoassay
US4794191A (en) * 1981-07-01 1988-12-27 Eastman Kodak Company Fluorescent chelates
US4859777A (en) * 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4670572A (en) * 1981-07-01 1987-06-02 Eastman Kodak Company Phenolic fluorescent labels
US4837169A (en) * 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay
US4801722A (en) * 1981-07-01 1989-01-31 Eastman Kodak Company Coumarin chelates
US4767611A (en) * 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
EP0171978B1 (en) * 1984-08-13 1990-11-07 HSC Research Development Corporation 1,10-phenanthroline-2,9-dicarboxylic acid-derivatives and their use in fluorescent immunoassay
DK365785A (da) * 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US5075447A (en) * 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
US4761481A (en) * 1985-03-18 1988-08-02 Baxter Travenol Laboratories, Inc. Substituted pyridine derivatives
SE8502573D0 (sv) * 1985-05-23 1985-05-23 Jouko Kanakre Fluorescent lanthanide chelates useful as labels of physiologically active materials
DE3789430T2 (de) * 1986-06-17 1994-10-27 Baxter Diagnostics Inc Homogenes fluortestverfahren mit abstoss des fluorzenten hintergrundes.
AU8152887A (en) * 1986-10-17 1988-05-06 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4933352A (en) 1987-03-31 1990-06-12 Spyros Theodoropulos Bi-functional carbamates of 2-ureado-pyridine compounds
SE8702824L (sv) * 1987-07-10 1989-01-11 Wallac Oy Metall-kelaterande 2,6-disubstituerade pyridinfoereningar och deras anvaendning
US5032677A (en) * 1987-11-06 1991-07-16 Baxter International Inc. Fluorescent poly(arylpyridine) rare earth chelates
JPH082878B2 (ja) * 1988-02-12 1996-01-17 富士写真フイルム株式会社 ４’−アルコキシ−２，２’：６’，２〃−デルピリジン誘導体及びその金属錯体
SE8800613D0 (sv) * 1988-02-23 1988-02-23 Wallac Oy A novel spectrofluorometric method and compounds that are of value for the method
US4917878A (en) 1988-05-02 1990-04-17 Thomas Jefferson University Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals
SE8802575D0 (sv) * 1988-07-08 1988-07-08 Wallac Oy Terpyridine derivatives
US5202423A (en) * 1988-07-08 1993-04-13 Wallac Oy Terpyridine derivatives
FR2644785B1 (fr) * 1989-03-24 1991-07-05 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes metalliques formes par ces ligands et composition de diagnostic les contenant
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods

Also Published As

Publication number Publication date
HU9301328D0 (en) 1993-10-28
WO1992008494A2 (en) 1992-05-29
FI932083A0 (fi) 1993-05-07
CA2095123A1 (en) 1992-05-09
WO1992008494A3 (en) 1993-07-08
NO931631L (no) 1993-06-23
PT99460A (pt) 1992-09-30
US5367080A (en) 1994-11-22
NZ240521A (en) 1995-01-27
FI932083A7 (fi) 1993-07-02
IE913907A1 (en) 1992-05-20
EP0624097A1 (en) 1994-11-17
PT99460B (pt) 1999-02-26
ATE164082T1 (de) 1998-04-15
US5707603A (en) 1998-01-13
KR930701974A (ko) 1993-09-08
BR9107074A (pt) 1993-09-21
AU9029191A (en) 1992-06-11
DE69129127D1 (de) 1998-04-23
AU667030B2 (en) 1996-03-07
JP3292301B2 (ja) 2002-06-17
HUT67298A (en) 1995-03-28
TW201271B (es) 1993-03-01
EP0624097B1 (en) 1998-03-18
JPH06501703A (ja) 1994-02-24
US5677445A (en) 1997-10-14
AU5583596A (en) 1996-08-01
NO931631D0 (no) 1993-05-05
MX9101999A (es) 1992-06-01
GR3026713T3 (en) 1998-07-31
US5523402A (en) 1996-06-04
DK0624097T3 (da) 1998-10-19
DE69129127T2 (de) 1998-10-08

Similar Documents

Publication Publication Date Title
ES2113892T3 (es) Inmunoreactivos radiactivos dirigidos.
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
DE3683528D1 (de) Tetrapyrrol-therapiemittel.
ES2123654T3 (es) Carbapenems que contienen un grupo fenilo substituido con carboxi, procesos para su preparacion, productos intermedios y uso como antibioticos.
MX9202996A (es) Diazabiciclo-(3-3-1)nonanos.
JPS5569586A (en) 11* 66 and 22substitutedd11carbaa22penenn 33carboxylic acid
DK250181A (da) Fremgangsmaade til fremstilling af vinblastinderivater
GR1001072B (el) Διαφανες αντιιδρωτικο σε ραβδο.
ATE33635T1 (de) Substituierte sulfonamidbenzamide, antiarythmische mittel und deren zusammensetzungen.
DE3581699D1 (de) Bis-dimethoxymethyl(trimethoxybenzyl)isochinolinium-salze, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3267039D1 (en) Stable s-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle
DK173883D0 (da) Substituerede 8-phenylxanthiner
FR2707300B1 (fr) Composition de savon solide, transparente, à base de sels d'acides gras contenant de l'isoprèneglycol.
NO163331C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 6,7-disubstituerte 1-cyklopropyl-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyrer.
KR920007639A (ko) 방사능의약품 조성물의 제조방법
ATE164836T1 (de) Sulfobernsteinsäurediester enthaltende flüssige formulierungen
ATE172108T1 (de) Verwendung von diglycerinestern gegen unreine haut
DE3785046A1 (es)
ATE203168T1 (de) Komplexbildnermittel und zielimmunoreagenzien
Jensen et al. Chloracne: three cases
JPS5750928A (en) Diagnostic agent for scanning bone
PT89729A (pt) Processo para a preparacao de derivados de cefalosporina e de composicoes farmaceuticas que os contem
SE8005714L (sv) Acetoximetyl-penamforeningar anvendbara som beta-laktamasinnibitorer
AR224877A1 (es) Nuevos 3,4,5-trihalofenol esteres de acidos carboxilicos alifaticos o aromaticos,composiciones antimicrobianas que contienen estos esteres y procedimiento para proteger material mediante tratamiento con dichos compuestos o composiciones
ES476754A1 (es) Procedimiento para la preparacion de una composicion anti- biotica acuosa parenteral de color y ph estabilizados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624097

Country of ref document: ES